immune checkpoint receptor blockers, such as anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T lymphocyte associated protein 4 (CTLA-4), enhance anti-tumor immune response by targeting T lymphocyte regulatory pathways, and have achieved great progress10. Here, PDCD1 is linked to neoplasm.